NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of California, San Diego
Exelixis
Hoffmann-La Roche
Numab Therapeutics AG
HiberCell, Inc.
Boston Scientific Corporation
Intensity Therapeutics, Inc.
Sirtex Medical
BeiGene
Imunon
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Kyowa Kirin Co., Ltd.
MedImmune LLC
H. Lee Moffitt Cancer Center and Research Institute
University of California, San Diego
Daiichi Sankyo
Symphogen A/S
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pfizer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eisai Inc.
Generic Devices Consulting, Inc.
Norwegian Department of Health and Social Affairs
Washington University School of Medicine
Yale University
University of Pittsburgh
Merck KGaA, Darmstadt, Germany
Bayer
Novartis
Bristol-Myers Squibb
Novartis
National Institutes of Health Clinical Center (CC)